NCT02746328View on ClinicalTrials.gov

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
ER+ and AR+ Breast Cancer
Interventions
DRUG

GTx-024 9 or 18 mg

Patients enrolled in G200802 receiving GTx-024 9 or 18 mg

Trial Locations (1)

98109

University of Washington, School of Medicine, Seattle

Sponsors

Lead Sponsor

GTx
All Listed Sponsors
lead

GTx

INDUSTRY

NCT02746328 - Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass | Biotech Hunter | Biotech Hunter